SEC Form 4 · accession 0001654954-19-000085
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean A Power
Officer — CFO, Secretary and Treasurer
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 7:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF2,F3 | Jan 2, 2019 | S | 37,275 | $4.13 | D | 400,992 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $4.10 | Dec 31, 2018 | A | 115,000 | A | — | Dec 31, 2028 | Common Stock | 115,000 | 115,000 | D |
Explanation of responses
- F1In connection with the vesting of 72,500 shares on January 1, 2019, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
- F2Represents the weighted average sales price.
- F3Includes shares of restricted Common Stock, which are subject to vesting.
- F4The options vest according to the following schedule: 25% on each of January 1, 2020, January 1, 2021, January 1, 2022, and January 1, 2023.